Technical Analysis for SYRS - Syros Pharmaceuticals, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Up | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 50 DMA Resistance | Bearish | 1.47% | |
| Bollinger Band Squeeze | Range Contraction | 1.47% | |
| BB Squeeze Started | Range Contraction | 1.47% | |
| Gapped Down | Weakness | 1.47% | |
| 50 DMA Resistance | Bearish | 0.91% | |
| Bearish Engulfing | Bearish | 0.91% | |
| 50 DMA Resistance | Bearish | 0.36% | |
| Shooting Star Candlestick | Bearish | 0.36% | |
| Doji - Bearish? | Reversal | 0.36% | |
| Earnings Movers | Other | 0.36% |
| Alert | Time |
|---|---|
| Upper Bollinger Band Resistance | 3 minutes ago |
| Up 2% | 9 minutes ago |
| Rose Above Previous Day's High | 21 minutes ago |
| Rose Above Upper Bollinger Band | 21 minutes ago |
| 60 Minute Opening Range Breakout | about 1 hour ago |
Get this analysis on your stocks daily!
- Earnings date: 05/14/2024
Syros Pharmaceuticals, Inc. Description
Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing medicines that control genes to transform the lives of patients with cancer, immune-mediated diseases, and other diseases. The company's gene control platform identifies gene control targets linked to genomically defined patient populations and drugging gene control targets; identifies potential new drug targets across a range of diseases; provides lens for diagnosing and segmenting patients, including those with complex/multi-factorial diseases; and allows users to advance a wave of medicines with the potential to influence multiple drivers of disease through a single target. Its pipeline includes SY-1425, a selective RARa agonist for genomically defined subsets of patients with relapsed or refractory acute myeloid leukemia and relapsed high-risk myelodysplastic syndrome; and SY-1365, a selective CDK7 inhibitor for acute leukemia. Syros Pharmaceuticals, Inc. was formerly known as LS22, Inc. Syros Pharmaceuticals, Inc. was founded in 2011 and is based in Cambridge, Massachusetts.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Disease Medication Acute Myeloid Leukemia Leukemia Myelodysplastic Syndrome Immune Mediated Diseases Acute Leukemia Refractory Acute Myeloid Leukemia
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 8.17 |
| 52 Week Low | 2.0902 |
| Average Volume | 185,754 |
| 200-Day Moving Average | 4.89 |
| 50-Day Moving Average | 5.47 |
| 20-Day Moving Average | 5.20 |
| 10-Day Moving Average | 5.21 |
| Average True Range | 0.34 |
| RSI (14) | 53.70 |
| ADX | 16.63 |
| +DI | 30.16 |
| -DI | 16.48 |
| Chandelier Exit (Long, 3 ATRs) | 4.83 |
| Chandelier Exit (Short, 3 ATRs) | 5.43 |
| Upper Bollinger Bands | 5.57 |
| Lower Bollinger Band | 4.83 |
| Percent B (%b) | 0.83 |
| BandWidth | 14.29 |
| MACD Line | -0.02 |
| MACD Signal Line | -0.10 |
| MACD Histogram | 0.075 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 5.80 | ||||
| Resistance 3 (R3) | 5.78 | 5.65 | 5.74 | ||
| Resistance 2 (R2) | 5.65 | 5.56 | 5.66 | 5.72 | |
| Resistance 1 (R1) | 5.55 | 5.51 | 5.60 | 5.57 | 5.70 |
| Pivot Point | 5.42 | 5.42 | 5.45 | 5.43 | 5.42 |
| Support 1 (S1) | 5.32 | 5.33 | 5.37 | 5.34 | 5.20 |
| Support 2 (S2) | 5.19 | 5.28 | 5.20 | 5.18 | |
| Support 3 (S3) | 5.09 | 5.19 | 5.16 | ||
| Support 4 (S4) | 5.11 |
